179
edits
Changes
Jump to navigation
Jump to search
public policy
== Public Policy ==
The RNS System was approved by Food and Drug Administration (FDA) in 2013 based on clinical studies. Those contain a Feasibility study, a Pivotal study, and a Long-term Treatment study. There were also several studies in laboratory, where were tested every single device of the RNS System. Before human studies, there were also studies on animals, particularly on sheep. The Feasibility study contained 65 subjects and was aimed on preliminary safety and effectiveness. The results of the Feasibility study was used in the Pivotal study, which was performed ''"to establish a reasonable assurance of safety and effectiveness of the RNS System"''. <ref name="SSFD">Summary of Safety and Effectiveness Data (SSED). U.S. Food & Drug Administration [online]. 2013. Available online at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100026B.pdf (Retrieved 4.11.2016)</ref>
The RNS System devices are connected with several patents. On the website of the NeuroPace company, there are list of the patents for every single device of RNS System: NeuroPace® RNS® Neurostimulator, NeuroPace® Depth Lead, NeuroPace® Cortical Strip Lead, NeuroPace® Programmer, NeuroPace® Remote Monitor, Wand and Ferrule.<ref name="NeuroPace_patents">NeuroPace. Legal Terms. NeuroPace, Inc. [online]. © 2016. Available online at: http://www.neuropace.com/legal/ (Retrieved 30.11.2016)</ref>
